Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: N-Functionalization Determines the Multitarget Anti-Alzheimer's Activity Profile

GF. Makhaeva, NV. Kovaleva, NP. Boltneva, EV. Rudakova, SV. Lushchekina, TY. Astakhova, IV. Serkov, AN. Proshin, EV. Radchenko, VA. Palyulin, J. Korabecny, O. Soukup, SO. Bachurin, RJ. Richardson

. 2022 ; 27 (3) : . [pub] 20220204

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22011062

Grant support
19-53-26016_a Russian Foundation for Basic Research
0090-2019-0005 IPAC RAS State Targets Project
20-29633J Czech Science Foundation
N/A Alternatives Research and Development Foundation
N/A Mcubed

Using two ways of functionalizing amiridine-acylation with chloroacetic acid chloride and reaction with thiophosgene-we have synthesized new homobivalent bis-amiridines joined by two different spacers-bis-N-acyl-alkylene (3) and bis-N-thiourea-alkylene (5) -as potential multifunctional agents for the treatment of Alzheimer's disease (AD). All compounds exhibited high inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity for BChE. These new agents displayed negligible carboxylesterase inhibition, suggesting a probable lack of untoward drug-drug interactions arising from hydrolytic biotransformation. Compounds 3 with bis-N-acyl-alkylene spacers were more potent inhibitors of both cholinesterases compared to compounds 5 and the parent amiridine. The lead compounds 3a-c exhibited an IC50(AChE) = 2.9-1.4 μM, IC50(BChE) = 0.13-0.067 μM, and 14-18% propidium displacement at 20 μM. Kinetic studies of compounds 3a and 5d indicated mixed-type reversible inhibition. Molecular docking revealed favorable poses in both catalytic and peripheral AChE sites. Propidium displacement from the peripheral site by the hybrids suggests their potential to hinder AChE-assisted Aβ42 aggregation. Conjugates 3 had no effect on Aβ42 self-aggregation, whereas compounds 5c-e (m = 4, 5, 6) showed mild (13-17%) inhibition. The greatest difference between conjugates 3 and 5 was their antioxidant activity. Bis-amiridines 3 with N-acylalkylene spacers were nearly inactive in ABTS and FRAP tests, whereas compounds 5 with thiourea in the spacers demonstrated high antioxidant activity, especially in the ABTS test (TEAC = 1.2-2.1), in agreement with their significantly lower HOMO-LUMO gap values. Calculated ADMET parameters for all conjugates predicted favorable blood-brain barrier permeability and intestinal absorption, as well as a low propensity for cardiac toxicity. Thus, it was possible to obtain amiridine derivatives whose potencies against AChE and BChE equaled (5) or exceeded (3) that of the parent compound, amiridine. Overall, based on their expanded and balanced pharmacological profiles, conjugates 5c-e appear promising for future optimization and development as multitarget anti-AD agents.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011062
003      
CZ-PrNML
005      
20220506131021.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules27031060 $2 doi
035    __
$a (PubMed)35164325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Makhaeva, Galina F $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/0000000281366906
245    10
$a Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: N-Functionalization Determines the Multitarget Anti-Alzheimer's Activity Profile / $c GF. Makhaeva, NV. Kovaleva, NP. Boltneva, EV. Rudakova, SV. Lushchekina, TY. Astakhova, IV. Serkov, AN. Proshin, EV. Radchenko, VA. Palyulin, J. Korabecny, O. Soukup, SO. Bachurin, RJ. Richardson
520    9_
$a Using two ways of functionalizing amiridine-acylation with chloroacetic acid chloride and reaction with thiophosgene-we have synthesized new homobivalent bis-amiridines joined by two different spacers-bis-N-acyl-alkylene (3) and bis-N-thiourea-alkylene (5) -as potential multifunctional agents for the treatment of Alzheimer's disease (AD). All compounds exhibited high inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity for BChE. These new agents displayed negligible carboxylesterase inhibition, suggesting a probable lack of untoward drug-drug interactions arising from hydrolytic biotransformation. Compounds 3 with bis-N-acyl-alkylene spacers were more potent inhibitors of both cholinesterases compared to compounds 5 and the parent amiridine. The lead compounds 3a-c exhibited an IC50(AChE) = 2.9-1.4 μM, IC50(BChE) = 0.13-0.067 μM, and 14-18% propidium displacement at 20 μM. Kinetic studies of compounds 3a and 5d indicated mixed-type reversible inhibition. Molecular docking revealed favorable poses in both catalytic and peripheral AChE sites. Propidium displacement from the peripheral site by the hybrids suggests their potential to hinder AChE-assisted Aβ42 aggregation. Conjugates 3 had no effect on Aβ42 self-aggregation, whereas compounds 5c-e (m = 4, 5, 6) showed mild (13-17%) inhibition. The greatest difference between conjugates 3 and 5 was their antioxidant activity. Bis-amiridines 3 with N-acylalkylene spacers were nearly inactive in ABTS and FRAP tests, whereas compounds 5 with thiourea in the spacers demonstrated high antioxidant activity, especially in the ABTS test (TEAC = 1.2-2.1), in agreement with their significantly lower HOMO-LUMO gap values. Calculated ADMET parameters for all conjugates predicted favorable blood-brain barrier permeability and intestinal absorption, as well as a low propensity for cardiac toxicity. Thus, it was possible to obtain amiridine derivatives whose potencies against AChE and BChE equaled (5) or exceeded (3) that of the parent compound, amiridine. Overall, based on their expanded and balanced pharmacological profiles, conjugates 5c-e appear promising for future optimization and development as multitarget anti-AD agents.
650    _2
$a acetylcholinesterasa $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    _2
$a aminochinoliny $x chemie $7 D000634
650    _2
$a antioxidancia $x chemie $x farmakologie $7 D000975
650    _2
$a butyrylcholinesterasa $x chemie $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemie $x farmakologie $7 D002800
650    _2
$a GPI-vázané proteiny $x antagonisté a inhibitory $7 D058851
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a molekulární modely $7 D008958
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a neuroprotektivní látky $x chemie $x farmakologie $7 D018696
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kovaleva, Nadezhda V $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/0000000249905068
700    1_
$a Boltneva, Natalia P $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/0000000271718832
700    1_
$a Rudakova, Elena V $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/0000000246007799
700    1_
$a Lushchekina, Sofya V $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $u Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia $1 https://orcid.org/000000026922020X
700    1_
$a Astakhova, Tatiana Yu $u Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia $1 https://orcid.org/0000000230349698
700    1_
$a Serkov, Igor V $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia
700    1_
$a Proshin, Alexey N $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/0000000239705767
700    1_
$a Radchenko, Eugene V $u Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia $1 https://orcid.org/0000000220917022
700    1_
$a Palyulin, Vladimir A $u Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia $1 https://orcid.org/0000000187928386
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000169777596 $7 xx0119837
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Bachurin, Sergey O $u Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia $1 https://orcid.org/000000033637818X
700    1_
$a Richardson, Rudy J $u Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI 48109, USA $u Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA $u Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA $u Michigan Institute for Computational Discovery and Engineering, University of Michigan, Ann Arbor, MI 48109, USA $1 https://orcid.org/0000000220285723
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 27, č. 3 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35164325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131013 $b ABA008
999    __
$a ok $b bmc $g 1788918 $s 1162260
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 27 $c 3 $e 20220204 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a 19-53-26016_a $p Russian Foundation for Basic Research
GRA    __
$a 0090-2019-0005 $p IPAC RAS State Targets Project
GRA    __
$a 20-29633J $p Czech Science Foundation
GRA    __
$a N/A $p Alternatives Research and Development Foundation
GRA    __
$a N/A $p Mcubed
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options